Comment from American Society of Transplantation

Summary: The American Society of Transplantation supports the FDA's efforts to identify mechanisms for drug repurposing, particularly for solid organ transplant recipients. They argue that many evidence-supported therapies are currently used off-label due to small patient populations and limited commercial incentives, creating administrative burdens and potential delays in patient care.